KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $445.7 million.

  • Jazz Pharmaceuticals' Cost of Revenue rose 15.47% to $128.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.8 million, marking a year-over-year increase of 11.69%. This contributed to the annual value of $445.7 million for FY2024, which is 2.33% up from last year.
  • Jazz Pharmaceuticals' Cost of Revenue amounted to $445.7 million in FY2024, which was up 2.33% from $435.6 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Cost of Revenue high stood at $540.5 million for FY2022, and its period low was $148.9 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $445.7 million (2024), whereas its average is $473.9 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 195.98% in 2021, then declined by 19.41% in 2023.
  • Yearly analysis of 5 years shows Jazz Pharmaceuticals' Cost of Revenue stood at $148.9 million in 2020, then surged by 195.98% to $440.8 million in 2021, then climbed by 22.63% to $540.5 million in 2022, then dropped by 19.41% to $435.6 million in 2023, then rose by 2.33% to $445.7 million in 2024.